Large med-tech companies will have to continue to look toward M&A activities to supplement slower organic growth in mature markets, according to The Walden Group's (Tarrytown, New York), 2010 report. The 30-page document, which includes acquisitions in the medical device sector, highlights seven key deals or those transactions with a value of more than $100 million. (Medical Device Daily) Read More
